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In response to the global burden of liver disease there has been a commensurate
increase in the demand for liver transplantation. However, due to a paucity of donor
organs many centers have moved toward the routine use of marginal allografts, which
can be associated with a greater risk of complications and poorer clinical outcomes.
Mesenchymal stromal cells (MSC) are a multi-potent progenitor cell population that
have been utilized to modulate aberrant immune responses in acute and chronic
inflammatory conditions. MSC exert an immunomodulatory effect on innate and adaptive
immune systems through the release of both paracrine soluble factors and extracellular
vesicles. Through these routes MSC can switch the regulatory function of the immune
system through effects on macrophages and T regulatory cells enabling a switch of
phenotype from injury to restoration. A key benefit seems to be their ability to tailor
their response to the inflammatory environment without compromising the host ability
to fight infection. With over 200 clinical trials registered to examine MSC therapy in liver
disease and an increasing number of trials of MSC therapy in solid organ transplant
recipients, there is increasing consideration for their use in liver transplantation. In this
review we critically appraise the potential role of MSC therapy in the context of liver
transplantation, including their ability to modulate reperfusion injury, their role in the
reduction of medium term complications in the biliary tree and their potential to enhance
tolerance in transplanted organs.
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INTRODUCTION
Although the global burden of liver pathology is often underestimated due to limitations in
mortality recording systems in many countries (1), it is still estimated that over 2 million liver-
related deaths occur worldwide (2). Whilst there are many causes of liver disease, end stage liver
disease represents a shared final pathway and once reached, the only curative treatment remains
liver transplantation (3). With increasing numbers of patients on transplant waiting lists and fewer
donor organs there has been a move toward the use of marginal donor organs so as to increase
the pool of available organs for transplantation (4). This comes at a clinical cost though, despite
improvements in patient selection. Specifically the prolonged warm ischemic time in a donation
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after cardiac death (DCD) liver transplant results in increased
morbidity, mortality, critical care stay, and overall cost (5).
The ability to increase the donor pool further by pushing the
boundaries of ischemia, as well as reducing the need for toxic
immunosuppression could lead to a reduction in complications
and an increased number of organs available for transplantation.
Mesenchymal stromal cells (MSC) may offer a novel cell
therapeutic approach to impact on these negative squeal and
potentially allow for expansion of the donor pool.
TRANSPLANT RELATED HEPATIC INJURY
The process of liver transplantation includes a combination
of both warm ischemia (organ at body temperature) and
cold ischemia (organ perfused with cold preservative solution).
The relative contribution of these processes during organ
retrieval depends principally on the transport duration of
the donor organ after cold preservation (6) and the donor
liver source (7). Broadly speaking donor livers can come
from one of three sources; a living donor, a brainstem
dead/heart beating donor (donation after brainstem death,
DBD) or a donor undergoing circulatory arrest/non-heart
beating donor (donation after circulatory death, DCD). The
consequences of the prolonged warm ischemia seen in DCD
include greater generation of reactive oxygen species and
a delayed adaptive immune response resulting in an injury
pattern characterized by hepatocyte loss as opposed to the
predominantly endothelial injury seen following DBD (8). Biliary
complications are often seen following liver transplantation,
however their incidence is different when comparing DCD and
DBD with a greater incidence of ischemic cholangiopathy in
DCD compared with more strictures and bile duct leaks seen
in DBD (9). Liver ischemia and reperfusion injury represent
a complex combination of pathologies with a variety of cell
types involved and a number of pre-disposing factors related
to both the transplant recipient and the donor organ. Ischemia
and reperfusion injury are distinct but related pathologies often
considered together as ischemia/reperfusion injury (10), with
ischemic injury representing the primary damage to cells due
to an interruption in organ perfusion and reperfusion injury
representing the immunological response to the generation of
reactive oxygen species and products of cell death following the
re-establishment of organ perfusion.
Ischaemic injury occurs as a result of an inadequate oxygen
supply to an organ and one of the first descriptions of liver
ischemia was by Pringle in which his eponymous maneuver
was shown to reduce bleeding by occluding liver vasculature
(11). During liver transplantation warm ischemia can be further
subdivided into donor warm ischemic time which is defined as
the time from withdrawal of life support to the initiation of
cold storage, and graft warm ischemic time which is defined
as the time from removal from cold storage until reperfusion
has occurred (12). There should be little donor warm ischemic
time in living donors or DBD donors, whereas DCD donors
will have a longer period of warm ischemia (Figure 1). The
amount of cellular dysfunction seen following an ischemic insult
FIGURE 1 | Pathway demonstrating the differences between DBD and DCD
liver transplantation with no donor warm ischemic time seen in DBD compared
with a variable amount of donor warm ischemia in DCD.
is related to both the extent and duration of the period of
ischemia (13). In humans oxygen is utilized in aerobic respiration
in order to generate Adenosine Triphosphate (ATP), an energy
source required for metabolic processes (14). Fermentation of
glucose (often referred to in human physiology as anaerobic
respiration) occurs when there is no oxygen present to act
as the terminal electron acceptor leading to the generation of
lactate, a less efficient process of energy production leading to
the generation of H+ ions and the subsequent reduction in
cellular pH. The subsequent H+ ion gradient leads to activation
of Na+/H+ transporters in order to correct the intracellular
pH generating an osmotic gradient and leading to cellular
edema (15). Depletion of ATP also leads to inactivation of
other ion pumps including the ATP dependent Ca2+ channels
(Figure 2). There is also an increase in the breakdown products
of ATP including xanthine and hypoxanthine (16). Hepatocytes
are particularly vulnerable to warm ischemia (17) and whilst
there is some debate over whether necrosis or apoptosis is the
predominant factor in hepatocyte death, both modes of cell loss
demonstrate mitochondrial dysfunction as a key problem (18–
20). Cold ischemia, or preservation related injury, confers similar
problems to that of warm ischemia, however there seems to be an
increased effect on the sinusoidal endothelial cells whose death at
reperfusion has been shown to be related to the duration of cold
ischemia through platelet induced apoptosis (21).
Following restoration of blood and oxygen supply to the
ischemic liver further damage occurs in the form of reperfusion
injury. The generation of reactive oxygen species (ROS) is a key
mechanism in this process, initially produced by intracellular
xanthine oxidize in combination with resident specialized
macrophages (Kupffer cells) and infiltrating polymorphonuclear
cells (22). Activated Kupffer cells release pro-inflammatory
cytokines which enhance neutrophil recruitment leading
to further propagation of ROS release (23, 24). Following
reperfusion sinusoidal endothelial cells express a number
of adhesion molecules aiding the recruitment of infiltrating
immune cells (25). T lymphocyte, in particular CD4+ cells, is
a key mechanism of injury following reperfusion (Figure 2)
and blocking CD4+ recruitment leads to a significant reduction
injury (26). Activation of Toll Like Receptors (TLR) in
particular TLR4 by damage associated molecular patterns
(DAMP) has also been shown to be an important cause of
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FIGURE 2 | Diagram representing hepatic ischemic and reperfusion injury.
Ischemia is characterized by a lack of oxygen supply leading to a depletion of
ATP and cellular edema due to increased H+ leading to activation of the
Na+/H+ transporter and inactivation of the ATP dependent Ca2+ pump.
Reperfusion leads to restoration of O2 supply with ROS generation and
recruitment of neutrophils and CD4+ lymphocytes.
reperfusion injury with reduced damage when this pathway is
inhibited (27, 28).
MESENCHYMAL STROMAL CELLS
Mesenchymal stromal cells (MSC) are a multi-potent
progenitor cell type capable of tri-lineage differentiation
and immunomodulation (29). The description of cells in the
bone marrow able to perform a supportive role was postulated
over a century ago, however more recent work has developed
the understanding of the physiological role that MSC play in
the bone marrow stem cell niche (30). MSC do not appear to
be limited to the bone marrow however, with MSC populations
described in umbilical cord (31), placenta (32), adipose tissue
(33), dermal tissue (34), and dental pulp (35). Debate still
remains in the literature as to what constitutes an MSC and
whether they represent true stem cells (36, 37) with the early
literature plagued by problems with heterogeneous cells types
and isolation techniques. With the advent of cell sorting and the
publication of minimal criteria in order to describe MSC some
of the problems seen in the earlier literature have improved
but comparison between MSC types can still be problematic
(29, 38, 39). Whilst the functional role that MSC play is still not
fully elicited their ability to modulate the immune system has
been well described (40, 41). Variation in human MSC function
has been variably ascribed to different batches, donor sources
and donor age, however evidence is mixed and there is as yet
no standardized source or donor demographic definition to
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inform cell therapy in clinical trials (42–47). It has also been
demonstrated that adipose MSC derived from obese donors have
reduced proliferative and differentiation ability (48). MSC tissue
source may be important due to differing expression of tissue
factor/CD142, as whilst MSC have low levels of MHC Class I and
no MHC Class II expression (49), an innate immune response
can be triggered following MSC infusion with source and passage
being major determinants of tissue factor expression (50). This
innate immune response can trigger thrombosis and lead to
micro and microvascular complications. This is an important
consideration when designing clinical trials as a cell therapy
with low tissue factor expression may reduce the potential
risks associated with MSC administration or enable steps to be
made to mitigate these effects such as co-administration with
heparin (51).
There have been a number of mechanisms described by which
MSC are able to suppress the immune systemwith effects on both
the innate and adaptive components. A key ability supporting the
potential use of MSC in liver transplantation is their ability to
suppress T cell activation and proliferation. Bonemarrow derived
MSC can upregulate the cyclin-dependent kinase inhibitor
p27Kip1 and inhibit cyclin D2 leading to early cell cycle arrest
in T lymphocytes (52). The effects on cyclin D2 are not limited to
T cells however, with evidence that inhibition of B lymphocytes
also occurs (53). MSC isolated from bonemarrow can also reduce
expression of MHC class I and II on dendritic cells, inhibiting
their maturation and subsequent immune cell activation (54, 55).
Another important ability of MSC is their effects on soluble
factors, both secreting themselves and stimulating or inhibiting
the secretion from other cells. Whilst many relevant mediators
have been shown to be modulated by MSC therapy (Table 1;
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FIGURE 3 | MSC are able to exert their effects in ischemic liver injury via a number of potential effector cells including CD4+ and CD8+ lymphocytes, NK cells,
Regulatory T cells and γδT cells. They are also able to support hepatocyte transplantation into injured liver and can undergo differentiation into hepatocytes.
Figure 3), important factors include Il-10, TNFα, IDO, PGE2,
and IFN-γ (56–62).
Given that MSC appear to exert their effect by secreting
soluble proteins and extra-cellular vesicles (MSC-EV)
administration of the bone marrow MSC secretome may
represent a potential therapeutic strategy avoiding some of the
potential problems with the use of a cellular therapy (63). In
particular, the ability of MSC-EV to transfer non-coding RNA
may explain the prolonged effects seen after the rapid clearance
of MSC from the systemic circulation (64).
There are a number of potential routes of administration
for MSC and extensive research carried out in animal models
has not revealed a consensus on the most efficient and effective
route of delivery. MSC are relatively large cells compared with
immune cells, and as such when administered systemically tend
to be filtered by the lungs (65). Both intravenous and intra-
arterial routes of administration have been described, however
concerns have been raised regarding the potential risk of cerebral
ischemia following intra-arterial administration of bone marrow
MSC (66), although there are diseases where spread to cerebral
tissue may be beneficial such as acute ischemic stroke (67).
Subcutaneous administration may represent an alternative as
there is evidence in graft versus host disease that bone marrow
derived MSC can exert a remote effect when encapsulated (68),
however these results have not been reproduced more widely.
Intravenous administration is commonly used in clinical and pre-
clinical investigation, however this can be problematic due to
cells becoming trapped in the lung (69). Human bone marrow
derived MSC have been demonstrated to express a number of
adhesion molecules on their surface, and whilst many of these
are lost in standard culture conditions, expression of CXCR4 is
increased in hypoxic culture which may MSC homing to injured
tissues (70, 71). Expression of CD44 has also been demonstrated
to be involved in MSC engraftment to injured liver tissue in vitro
suggesting direct administration or routes bypassing the lungs
may lead to greater engraftment to the target organ (72). In large
animal models of liver injury and liver fibrosis adipose tissue
derivedMSC have been injected via the intra-portal route directly
into the liver vasculature and have demonstrated efficacy without
an increase in intra-portal pressure, suggesting that this route is
feasible and safe and would be directly accessible during a liver
transplantation operation (73). Injection rate and needle gauge
has also been shown to be an important consideration when
administering MSC with optimum rates in a variety of cell types
described in vitro (74).
MSC have been successfully used in a variety of different liver
pathologies in both pre-clinical and clinical trials with no major
safety concerns identified (75), rendering their potential use in
liver transplantation a new and exciting prospect.
MSC IN ISCHEMIA/REPERFUSION INJURY
Due to their ability to modulate both innate and adaptive
immunity MSC represent an important potential therapy to
ameliorate ischemia/reperfusion injury in liver surgery and
transplantation. MSC have been shown to reduce ALT and IL-
6 when administered systemically in models of hepatic ischemia
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reperfusion injury, but notably only if given before the ischemic
insult (76). There also seems to be a reduction in TUNEL
positive hepatocytes indicating less apoptosis in rat models of
ischemia reperfusion injury following bonemarrow derivedMSC
therapy (77). An important concern in the context of significant
oxidative stress, as seen in both ischemia reperfusion injury and
other forms of liver injury such as acute hepatic failure, is the
ability of donor cells to survive in such a hostile environment.
Bone marrow and adipose derived MSC have been shown to be
resistant to oxidative stress and may themselves have antioxidant
properties further suggesting a therapeutic role in these types of
injury (78, 79).
Immune cell recruitment is a key feature in reperfusion injury
with animal studies demonstrating that a reduction in injury
can be achieved by blocking recruitment of both neutrophils
and lymphocytes (26, 80). MSC derived from bone marrow can
also reduce neutrophil recruitment and liver injury by enhancing
the intracellular activation of p38 MPK phosphorylation leading
to a decrease in the expression of CXCR2 on the surface
of neutrophils as well as reducing the production of the
neutrophil chemoattractant CXCL2 by inhibiting NK-κB p65
phosphorylation in macrophages (81). MSC-EV have also been
shown to reduce liver injury if given systemically prior to an
ischemic insult by reducing IL-6, IL10, TNFα, and IFN-γ levels
as well as the number of caspase 3 positive apoptotic cells (82).
In larger animal models of ischemia reperfusion injury
combined with partial hepatectomy, direct injection of MSC into
liver parenchyma following surgery has been shown to reduce
the number of apoptotic cells with a downregulation of Fas/Fas
ligand and a reduction in enzyme activity of caspase 3, caspase
8 and caspase 9. There was also an increase in the apoptosis
regulator protein Bcl2/Bax as well as a reduction in markers of
autophagy such as Beclin1, ATG5, and ATG12 (83), suggesting an
ability to regulate apoptosis in injured hepatocytes (84). Similar
findings have been shown in small animal models of ischemia
reperfusion injury (85). Topical application of adipose derived
MSC can also augment liver regeneration following reperfusion
injury with a reduction in necrotic areas and an increased
number of regenerating cells (76) with activation of the notch2
pathway in MSCs (86).
MSC AUGMENT HEPATOCYTE
ENGRAFTMENT AS AN ALTERNATIVE TO
WHOLE ORGAN TRANSPLANTATION
Hepatic ischemia reperfusion injury can lead to significant
hepatocyte loss with a subsequent loss of liver function. Over
the last two decades transplantation of human hepatocytes as an
alternative to whole organ transplantation has made significant
progress with the development of protocols for isolation and
storage of hepatocytes along with studies demonstrating early
efficacy (87). A major draw-back of hepatocyte transplantation is
the poor cell engraftment seen with only 0.1–0.3% hepatocytes
remaining in the recipient liver (88). Co-transplantation of
hepatocytes with fetal liver derived MSC has been shown to
augment engraftment with a greater number of hepatocytes
remaining in the recipient liver for a longer time along with
improved liver function in animal models (89). This ability
may as a result of MSC ability to provide tropic support to
hepatocytes (90).
In vitro studies in human pancreatic tissue have shown that
human bone marrow derived MSC can increase epithelial cell
proliferation and neovascularisation (91) andmore recent studies
in human pancreatic islet cell transplantation have demonstrated
that human bone marrow derived MSC are able to improve
survival of transplanted islet cells in animal models (92). The
ability of MSC to support transplanted pancreatic tissue via their
effects on both vascularisation and endothelial support suggest
an additional potential role in hepatocyte transplantation that
warrants further study.
As an alternative to hepatocyte transplantation it has been
argued that hepatocytes derived from MSC can replace injured
cells and improve liver function. Certainly the engraftment and
function of these cells appears to show benefit in animal models
of bone marrow MSC (93–95), however there are conflicting
results from pre-clinical studies rendering this a controversial
area still requiring considerable attention before becoming a
translatable therapy (96).
THERAPEUTIC STRATEGIES UTILIZING
MSC IN LIVER TRANSPLANTATION
Through their ability to reduce injury and cell death in models
of ischemia and reperfusion injury it stands to reason that there
is a role for MSC therapy in orthotopic liver transplantation
(OLT). Coupled with this the ability of MSC to promote liver
regeneration and reduce injury could lead to a further benefit in
the post-transplant recovery period (75).
Work in small animal models has been encouraging, where
adipose tissue derived MSC have been shown to reduce liver
injury and TUNEL positive hepatocytes in rat models of
liver transplantation (97). MSC derived conditioned media has
also shown a beneficial effect in pre-clinical models of liver
transplantation with a reduction in injury and an improvement
in liver function when 50% reduced size transplantation is
undertaken in rats with an increase in VGEF and MMP9
expression (98).
Indeed, a number of early phase clinical trials have been
undertaken in this patient cohort with some encouraging
results (99). Phase II clinical trials in patients undergoing liver
transplantation have shown safety, but were not powered to
demonstrate efficacy in patients receiving unrelated bonemarrow
derivedMSC in the first few days following transplantation (100).
MSC have also been tested for safety in a pilot study of patients
with acute allograft rejection following liver transplantation.
In patients treated with MSC in combination with standard
immunosuppression protocols for acute rejection there was a
significant increase in PGE2 and TGF-β1, as well as an significant
increase in FoxP3+ T regulatory cells isolated from peripheral
blood (101). The MYSTEP1 trial currently nearing completion
may provide safety information on the use of donor derived
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bonemarrowMSC in pediatric living donor liver transplantation,
paving the way for more extensive study in this cohort (102).
Normothermic machine perfusion is rapidly becoming a
therapy of interest in the preservation and regeneration of
donated livers (103, 104). In contrast to static cold storage, the
current gold standard for liver transplantation, normothermic
machine perfusion involves cannulation and perfusion of an
explanted liver at near physiologic conditions. This technique
has advantages over cold storage techniques which tend to
be poorly suited to steatotic grafts. With an interest in the
use of more marginal grafts to increase the potential pool
of donor organs reconditioning and regeneration of donor
organs is an area of increasing interest. MSC represent a
potential therapy to enhance the regeneration of donor liver
tissue. Proof of concept for delivery of MSC during machine
perfusion has recently been published paving the way for
further study (105). MSC appear to be retained in the
perfused liver and are still able to exert paracrine effects
on liver tissue, similar findings have been demonstrated in
porcine renal perfusion systems (106, 107). In renal perfusion,
the effects of perfusion on MSC has been studied in both
human and porcine bone marrow cells demonstrating that
perfusion amplifies the negative effects of cryopreservation
on MSC with lower levels of adhesion and an increase in
MSC reactive oxidative species (107). Currently normothermic
machine perfusion represents an interesting avenue and in
combination with cell therapy may represent a new future
standard in liver transplantation.
Another option for transplantation is the use of split
liver grafts (108, 109), an accepted technique for pediatric
transplantation, although a more mixed experience when
splitting a donor liver between two adult recipients. By
reducing ischemia/reperfusion injury at the time of surgery
and promoting post-operative liver regeneration an increased
number of patients could receive a transplantation if grafts
were routinely split between 2 recipients. MSC offer a
potential therapy to improve the outcomes in this type of
liver transplantation surgery with some encouraging animal
studies demonstrating reduction in TUNEL positive cells in
rat models of partial hepatectomy following MSC treatment
and improved survival in rat transplant models (110). MSC
are also able to promote regeneration in a 30% partial liver
transplant model by increasing the activity of AP-1 and NF-
κB as well as demonstrating increased expression of cyclin
D1 and proliferating cell nuclear antigen (PCNA) (111).
Similar principles could be applied to hepatic resection/partial
hepatectomy with improved regeneration allowing for greater
resection and therefore increased likelihood of adequate margins
in cancer surgery, and faster recovery times. So far animal work
has supported this with MSC therapy increasing both hepatocyte
and sinusoidal endothelial proliferation and recovery after partial
hepatectomy in mouse models (112). MSC conditioned media
can also promote liver regeneration in partial hepatectomy
models (113). MSC have also been suggested as a rescue
therapy for acute liver failure following partial hepatectomy.
In rat models, bone marrow MSC are able to improve
glucose metabolism and survival following 90% hepatectomy,
possibly through modulation of the AKT/GSK-3β/β-catenin
pathway (114).
In large animal models of 70% partial hepatectomy, MSC
therapy has been shown to improve both liver and renal function,
suggesting an initial benefit beyond liver regeneration (115).
This improvement was through correction of hemodynamic
dysfunction by increasing levels of platelet derived growth factor
(PDGF) along with promoting regeneration in the kidneys by
increasing pro regenerative cytokines.
MSC AS A THERAPY IN
POST-TRANSPLANT CARE
Following orthotopic liver transplantation, as with other organ
transplantation, patients are required to take immunosuppressive
agents in order to prevent the host immune system rejecting
the graft. In most cases this is lifelong therapy which conveys
a number of risks including infection and renal failure.
Most strategies employ the inhibition of T-cell proliferation.
By reducing or even eliminating immunosuppressant agents,
morbidity in patients who have received a donor organ would
be considerably reduced. MSC may offer an opportunity in
these patients due to their ability to suppress T cell proliferation
and activation.
Current consensus guidelines recommend the use of
calcineurin inhibitors for maintenance immunosuppression in
patients who receive a liver transplantation, supplemented with
anti-metabolites or m-TOR inhibitors (116). With this in mind
it is important to consider the effects of immunosuppressive
drugs on MSC as well as the potential additive effect of MSC
along with standard immunosuppressive agents used in liver
transplantation. In the short term (<7 days) exposure of MSC
from a variety of tissues to the calcineurin inhibitor tacrolimus,
the anti-metabolite mycophenolate or the m-TOR inhibitor
rapamycin, does not appear to lead to any detrimental effects.
Prolonged exposure however leads to MSC toxicity in the case
of tacrolimus, and reduced MSC proliferation in the case of
mycophenolate and rapamycin (117). The combination of drugs
seems to be important however with the effects of tacrolimus
on MSC being reversed by the combined use of oxytocin (118).
Whilst it has been demonstrated that avoidance of corticosteroids
in patients following a liver transplantation is likely to be safe
and reduce associated complications (119), corticosteroids are
still widely used in the setting of liver transplantation, both for
induction of immunosuppression and treatment of rejection
(120). When combined with dexamethasone in in vitro assays
the ability of MSC to suppress T cell proliferations seems to be
reversed (121), however the ability of MSC to suppress natural
killer cell activation seems to be enhanced with dexamethasone
augmenting the ability of MSC to IL-2 and IL-12 induced
CD69 expression and reduce production of IFNγ (122). This
effect appears to be through the blocking of STAT1 in MSC
by dexamethasone. MSC ability to suppress mononuclear
cells appears to be enhanced by both dexamethasone and
budesonide through increased IDO activity (123). In in vivo
mouse models MSC derived from induced pluripotent cells
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do not seem to be effected by concomitant administration of
dexamethasone (124). It would be challenging to test every
combination of drugs that a patients could be taking when
MSC therapy is administered, however the potential for both
synergy and antagonism of medications with MSC therapy
needs careful consideration when designing clinical trials in
liver transplantation.
In rat models of orthotopic liver transplantation MSC are able
to inhibit acute rejection by increasing expression of FoxP3T
regulatory cells (125), as well as prolonging survival by regulating
the expression of TGF-β1 (126). In early phase clinical trials
MSC have been shown to be safe in patients undergoing acute
rejection following transplantation, as well as demonstrating an
ability to increase TGF-β1 and prostaglandin E2 and increase the
percentage of T regulatory cells present (101). In small animal
models of cardiac and renal transplant allogeneic bone marrow
MSC are able to induce organ tolerance by down-regulating T
lymphocyte responses through expression of indolamine 2,3-
dioxygenase (127, 128). In rats, both recipient and donor derived
bone marrow MSC prolonged survival of transplanted livers
through induction of FoxP3T regulatory cells (125). Induction
of transplant tolerance is a promising area of research but as yet
has not made the transition into clinical studies.
Challenges With MSC Therapy
Whilst MSC appear to show a great deal of promise in
liver transplantation there are some challenges that need to
be overcome.
Heterogeneity
MSC heterogeneity has long been a problem due to an inability
to define and isolate a pure population of cells. The International
Society for Cell Therapy (ISCT) defined minimal criteria for
describing MSC in an attempt to overcome this but even
with these in place the cell populations used still represent a
heterogeneous population (29, 129, 130).
Immunogenicity and Haemocompatibility
Although MSC expression of MHC class II low/absent (49),
haemocompatibility has still been demonstrated to be an issue, as
MSC can upregulate class I and II MHC in response to interferon
gamma (131). In mouse models allogeneic bone marrow derived
MSC are cleared by the host immune system when transplanted
intoMHC class I and II mismatched recipients (132), and in graft
versus host disease bone marrow derived MSC seem to generate
an antibody response in a subset of patients (133). Despite
these findings, MSC still seem to illicit a much slower response
from the recipient immune system, coining the term “immune
evasive” (56). Meta-analysis seems to suggest that whilst bone
marrow derived cells appear to be safe, adipose tissue derived
and perinatal tissue MSC carry a risk of acute thrombosis due
to activation of the innate immune system (134–137). Problems
due to haemocompatibility can be mitigated by pre-screening in
clinical trials and has been suggested as a pre-requisite to cell
therapy (50).
Oncogenesis
MSC have long been studied in oncology where resident MSC
have been shown to support the tumor microenvironment
and are seen as a therapeutic target to reduce cancer growth
(138). It has been suggested that due to their ability to
support growth and activation that MSC therapy is at risk of
supporting or inducing tumor formation (139). Long term in
vitro studies of murine bone marrow MSC have demonstrated
TABLE 2 | Ongoing or recently completed clinical trials with MSC in liver transplantation.
References Study description Clinical Trial
Registration
Patients Status MSC Dose Key Findings
Detry et al. (100) Phase 1 trial testing MSC therapy in
liver transplantation for safety and
ability to induce tolerance
NCT01429038 19 Published 1.5-3 × 106/kg IV No side effects seen but
tolerance not induced
Remuzzi, G Test MSC ability to induce tolerance
following liver transplantation
NCT02260375 20 Recruiting 1-2 × 106/kg IV Not published
Soeder et al. (143) First in man case study of MAPC in
patients following liver transplant
(MiSOT-1)




Sturm, E Phase 1 trial to determine the safety
of MSC in pediatric liver
transplantation (MYSTEP1)
NCT02957552 7 Recruiting 2 doses 1 × 106/kg
intra-portal then IV
Not published
Walker et al. (144) Study the peripheral mobilization of
MSC following corticosteroid
administration in patients following
liver transplantation or liver resection
NCT02557724 35 Published N/A Reduction in MSC migration
following steroid
administration
Wang, F Phase 1 trial of MSC therapy to
induce tolerance following liver
transplantation
NCT01690247 50 Unknown IV, details not described Not published
Yang, Y To determine if MSC are safe in acute
rejection in ABO incompatible liver
transplantation (Phase 1/2)
NCT02706132 15 Unknown 6 doses 1 × 106/kg IV Not published
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the potential for oncogenic transformation (140), although this
has been questioned in more recent studies which suggest
there could have been cell line contamination (141). Whilst
some small studies have demonstrated this concern may be
valid, larger reviews of clinical trials do not support this
hypothesis, however vigilance is still required as with all clinical
trials (134).
CLINICAL TRIALS
There has been an explosion in the use of MSC in clinical
trials since the first study in humans carried out in 1995
(142), with MSC being one of the most clinically studied cell
therapies worldwide (39). Due to the types of ischemia and
reperfusion injury described earlier MSC represent a promising
therapy in many areas liver transplantation and post-transplant
care. Despite this, clinical trials in liver transplantation are still
early on in their development with very few published trials.
There have been few completed trials in patients undergoing
liver transplantation but some still ongoing (Table 2), all are
either phase 1 or phase 2 (145). This first published trials have
demonstrated safety ofMSC infusion in patients undergoing liver
transplantation, but have also failed to demonstrate a benefit
(100, 143). The effect of corticosteroids on patient’s peripheral
MSC populations has also been studied in the context of liver
transplantation with a reduction in circulating MSC seen in
those receiving corticosteroids (144). The implication of this
finding is difficult to put into context though as there are clear
differences between native and exogenous transplanted MSC in
both number and properties. Interestingly this may be further
proof of the pre-clinical studies suggesting that the MSC/HSC
niche is controlled in part by the sympathetic nervous system
(30). The ongoing MYSTEP1 trial is not only testing safety and
efficacy of donor derived bone marrow MSC, but also the intra-
portal route of administration in pediatric liver transplantation
(102). Due to the inherent complexity and heterogeneity of
clinical conditions, coupled with the variation in cell therapeutic
products due to differences in donor, batch and cell tissue
origin, the conduct and interpretation of clinical trials of MSC
is complex and challenging. Whilst trials of MSC therapy in
liver transplantation are still in their infancy, given the favorable
safety profile demonstrated so far there is more potential work
to be done in order to explore the role of MSC therapy in
these patients.
CONCLUDING REMARKS
Liver transplantation is a continually evolving field with
transplant teams consistently pushing the boundaries to enable
the scarce resource of a donor liver to confer greater benefit to
increasingly larger numbers of patients. Cell therapy with MSC
is an exciting treatment beginning to enter clinical trials that
may allow the boundaries to be pushed even further for a greater
patient benefit.
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